[Pharmacologic properties of a new, nonsteroidal anti-inflammatory agent, bucloxic acid (804 CB)].
D000284:Administration, Oral; D000311:Adrenal Glands / Q000502:physiology; D000700:Analgesics / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy; D003510:Cyclohexanes / Q000008:administration & dosage / Q000627:therapeutic use; D004487:Edema / Q000188:drug therapy; D004890:Erythema / Q000188:drug therapy; D006099:Granuloma / Q000188:drug therapy; D006168:Guinea Pigs; D006854:Hydrocortisone / Q000627:therapeutic use; D007213:Indomethacin / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007651:Keto Acids / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D010653:Phenylbutazone / Q000627:therapeutic use; D010654:Phenylbutyrates / Q000008:administration & dosage / Q000627:therapeutic use*; D011817:Rabbits; D051381:Rats
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D003510:Cyclohexanes; D007651:Keto Acids; D010654:Phenylbutyrates; D010653:Phenylbutazone; D006854:Hydrocortisone; D007213:Indomethacin
Etude des propriétés pharmacologiques d'un nouvel anti-inflammatoire, non stéroidique, l'acide bucloxique (804 CB)